胰管腺癌（PDAC）仍然是最致命的惡性腫瘤之一，儘管手術、化療和放射治療有所進展，五年存活率仍約為12%。現有的消融治療（RFA、微波、不可逆電穿孔）受到熱損傷風險以及鄰近血管／導管的限制。迫切需要能夠與全身性治療方案整合的新型局部治療。
適應症：Pancreatic Tumours
收案條件
納入條件
- Age ≥ 18 years old
- Fit for general anaesthesia
- Unresectable pancreatic cancer with, or without vascular encasement
- With or without distant metastasis
- Without portal vein thrombosis
- Good performance status:
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function
排除條件
- Refusal to take part in clinical trial
- Portal vein thrombosis present
- Not fit for general anaesthesia
- Poor general condition with limited life expectancy
- Uncontrolled coagulopathy
- Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年11月5日。